公开(公告)号：US20240398736A1

公开(公告)日：2024-12-05

申请号：US18266103

申请日：2021-09-01

Applicant: Tsubota Laboratory, Inc. ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kazuo Tsubota ,  Toshihide Kurihara ,  Shinichi Ikeda ,  Kiwako Mori ,  Xiaoyan Jiang

IPC: A61K31/192 ,  A61P27/10 ,  G01N33/50

Abstract: The present invention provides a screening method for searching a component inhibiting or treating scleral thinning, and eyedrops that contain the active ingredient, and hence can inhibit excessive thinning of the sclera, and as a result, can treat a posterior segment eye disease associated with the scleral thinning. The problems are solved by eyedrops containing, as an active ingredient, a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway. The problems are solved by a screening method for a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an indicator, influence on scleral thinning in the cell.

公开(公告)号：US20240041806A1

公开(公告)日：2024-02-08

申请号：US18266102

申请日：2021-09-01

Applicant: Tsubota Laboratory, Inc.

Inventor： Kazuo Tsubota ,  Toshihide Kurihara ,  Shinichi Ikeda ,  Kiwako Mori ,  Xiaoyan Jiang

IPC: A61K31/192 ,  A61K9/00 ,  A61P27/10 ,  G01N33/50

CPC classification number: A61K31/192 ,  A61K9/0048 ,  A61P27/10 ,  G01N33/5058

Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.